Zacks Research Has Positive Outlook of Medifast Q1 Earnings

Medifast, Inc. (NYSE:MED) – Equities researchers at Zacks Research lifted their Q1 2025 earnings per share estimates for shares of Medifast in a research report issued to clients and investors on Monday, March 10th. Zacks Research analyst R. Department now anticipates that the specialty retailer will post earnings of ($0.07) per share for the quarter, up from their prior estimate of ($0.10). The consensus estimate for Medifast’s current full-year earnings is $0.51 per share. Zacks Research also issued estimates for Medifast’s Q4 2025 earnings at $0.53 EPS, FY2025 earnings at $1.04 EPS, Q3 2026 earnings at $0.39 EPS and Q4 2026 earnings at $0.49 EPS.

Separately, DA Davidson decreased their price objective on shares of Medifast from $17.00 to $16.50 and set a “neutral” rating for the company in a research note on Wednesday, February 19th.

Medifast Price Performance

MED opened at $13.93 on Thursday. Medifast has a fifty-two week low of $13.57 and a fifty-two week high of $39.14. The firm has a market capitalization of $152.32 million, a P/E ratio of 77.37 and a beta of 1.13. The company’s 50-day moving average is $15.18 and its 200 day moving average is $17.39.

Medifast (NYSE:MED) last announced its quarterly earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.26. The business had revenue of $119.00 million during the quarter, compared to the consensus estimate of $114.25 million. Medifast had a return on equity of 10.64% and a net margin of 0.35%.

Institutional Trading of Medifast

Large investors have recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC raised its holdings in shares of Medifast by 4.1% in the 4th quarter. Exchange Traded Concepts LLC now owns 17,106 shares of the specialty retailer’s stock worth $301,000 after purchasing an additional 674 shares during the period. Northern Trust Corp raised its stake in Medifast by 0.9% in the 4th quarter. Northern Trust Corp now owns 101,775 shares of the specialty retailer’s stock valued at $1,793,000 after acquiring an additional 871 shares during the period. Centiva Capital LP lifted its holdings in Medifast by 6.3% during the third quarter. Centiva Capital LP now owns 15,238 shares of the specialty retailer’s stock valued at $292,000 after purchasing an additional 898 shares during the last quarter. Wells Fargo & Company MN boosted its position in Medifast by 23.5% during the fourth quarter. Wells Fargo & Company MN now owns 6,459 shares of the specialty retailer’s stock worth $114,000 after purchasing an additional 1,227 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Medifast by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 245,929 shares of the specialty retailer’s stock worth $4,335,000 after purchasing an additional 1,447 shares in the last quarter. Hedge funds and other institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.